Business Description
Hoth Therapeutics Inc
NAICS : 325411
SIC : 2833
ISIN : US44148G2049
Share Class Description:
HOTH: Ordinary SharesDescription
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 168.95 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 46.5 | |||||
| 3-Year EPS without NRI Growth Rate | 46.2 | |||||
| 3-Year FCF Growth Rate | 42 | |||||
| 3-Year Book Growth Rate | -38.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.89 | |||||
| 9-Day RSI | 35.52 | |||||
| 14-Day RSI | 39.26 | |||||
| 6-1 Month Momentum % | 19.19 | |||||
| 12-1 Month Momentum % | -14.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.89 | |||||
| Quick Ratio | 13.89 | |||||
| Cash Ratio | 13.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -100.7 | |||||
| Shareholder Yield % | -197.81 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -84.8 | |||||
| ROA % | -72.99 | |||||
| ROIC % | -15203.56 | |||||
| ROC (Joel Greenblatt) % | -13987.27 | |||||
| ROCE % | -81.78 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.57 | |||||
| Price-to-Tangible-Book | 0.57 | |||||
| EV-to-EBIT | 0.46 | |||||
| EV-to-EBITDA | 0.46 | |||||
| EV-to-FCF | 0.42 | |||||
| Price-to-Net-Current-Asset-Value | 0.58 | |||||
| Price-to-Net-Cash | 0.59 | |||||
| Earnings Yield (Greenblatt) % | 217.39 | |||||
| FCF Yield % | -148.98 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers